A respected RNAi therapeutics company.
We’ve also obtained a significant number of individual biopsy samples in this study with which we intend to perform molecular analyses for RNAi delivery and pharmacology. We expect to further update these outcomes at the annual ASCO conference in 2011.’ ‘Both primary liver malignancy and metastatic disease of the liver are connected with poor prognosis for patients, and new therapies are needed clearly. These interim data with multiple dosages of ALN-VSP, combined with data presented earlier in the year, are encouraging and we look forward to continued dosage escalation to explore potential and tolerability for tumor response,’ stated Howard A.Pichard, M.D., Pamela S. Douglas, M.D., Vinod H. Thourani, M.D., Vasilis C. Babaliaros, M.D., John G. Webb, M.D., Howard C. Herrmann, M.D., Joseph E. Bavaria, M.D., Susheel Kodali, M.D., David L. Brown, M.D., Bruce Bowers, M.D., Todd M. Dewey, M.D., Lars G. Svensson, M.D., Ph.D., Murat Tuzcu, M.D., Jeffrey W. Moses, M.D., Matthew R. Williams, M.D., Robert J. Siegel, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Stuart Pocock, Ph.D., Craig R. Smith, M.D., and Martin B. Leon, M.D. For the PARTNER Trial Investigators: Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis Symptomatic aortic stenosis, if left untreated, is characterized by a high threat of death.1-6 In the randomized Placement of Aortic Transcatheter Valves trial, transcatheter aortic-valve substitute , as compared with regular therapy, in individuals who were not regarded as suitable candidates for surgery, decreased the death rate at 12 months, reduced cardiac symptoms, and improved the hemodynamic functionality of the valve.2 Longer-term outcomes are essential to guide clinical practice decisions in this elderly patient population, in which most of the patients have multiple coexisting circumstances.